Tetrathiomolybdate
Colorectal Carcinoma
University of Michigan Rogel Cancer CenterPhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 73/ 100
Competitive context
161 Active assets in the Colorectal Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TIPIRACIL Mayo Clinic | Phase 2 | BBB |
FLUOROURACILUM City of Hope Medical Center | Phase 4 | BB |
Eloxatin First Affiliated Hospital of Zhejiang University | Phase 4 | BB |
MITOMYCIN C City of Hope Medical Center | Phase 3 | BB |
Capecitabine First Affiliated Hospital of Zhejiang University | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Tetrathiomolybdate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →